Pacific Biosciences of California, Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Pacific Biosciences of California, Inc. (PACB) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $80.03 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-02-26
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $21.84M, a 6.08% increase year-over-year.
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $20.34M, a 12.70% increase year-over-year.
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $16.55M, a 21.79% increase year-over-year.
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $21.29M, a 72.02% increase year-over-year.
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $80.03M, a 23.87% increase from fiscal 2016.
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $64.61M, a 72.28% increase from fiscal 2015.
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $37.50M, a 6.24% increase from fiscal 2014.
- Pacific Biosciences of California, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $35.30M, a 76.15% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $21.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $42.19M derived: sum of 2 quarters · filed 2018-02-26 | $58.74M derived: sum of 3 quarters · filed 2018-02-26 | $80.03M 10-K · filed 2018-02-26 |
| 2017-09-30 | $20.34M 10-Q · filed 2017-11-02 | $36.89M derived: sum of 2 quarters · filed 2017-11-02 | $58.19M 10-Q · filed 2017-11-02 | $78.78M derived: sum of 4 quarters · filed 2018-02-26 |
| 2017-06-30 | $16.55M 10-Q · filed 2017-08-02 | $37.84M 10-Q · filed 2017-08-02 | $58.44M derived: sum of 3 quarters · filed 2018-02-26 | $76.48M derived: sum of 4 quarters · filed 2018-02-26 |
| 2017-03-31 | $21.29M 10-Q · filed 2017-05-05 | $41.89M derived: sum of 2 quarters · filed 2018-02-26 | $59.94M derived: sum of 3 quarters · filed 2018-02-26 | $73.52M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-12-31 | $20.59M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $38.64M derived: sum of 2 quarters · filed 2018-02-26 | $52.23M derived: sum of 3 quarters · filed 2018-02-26 | $64.61M 10-K · filed 2018-02-26 |
| 2016-09-30 | $18.05M 10-Q · filed 2017-11-02 | $31.64M derived: sum of 2 quarters · filed 2017-11-02 | $44.02M 10-Q · filed 2017-11-02 | $53.81M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $13.59M 10-Q · filed 2017-08-02 | $25.97M 10-Q · filed 2017-08-02 | $35.77M derived: sum of 3 quarters · filed 2018-02-26 | $43.34M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $12.38M 10-Q · filed 2017-05-05 | $22.18M derived: sum of 2 quarters · filed 2018-02-26 | $29.75M derived: sum of 3 quarters · filed 2018-02-26 | $38.57M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $17.37M derived: sum of 2 quarters · filed 2018-02-26 | $26.19M derived: sum of 3 quarters · filed 2018-02-26 | $37.50M 10-K · filed 2018-02-26 |
| 2015-09-30 | $7.57M 10-Q · filed 2016-11-04 | $16.39M derived: sum of 2 quarters · filed 2016-11-04 | $27.70M 10-Q · filed 2016-11-04 | $40.63M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $8.82M 10-Q · filed 2016-08-04 | $20.13M 10-Q · filed 2016-08-04 | $33.06M derived: sum of 3 quarters · filed 2017-03-06 | $39.82M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $11.31M 10-Q · filed 2016-05-05 | $24.23M derived: sum of 2 quarters · filed 2017-03-06 | $30.99M derived: sum of 3 quarters · filed 2017-03-06 | $38.74M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $12.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $19.68M derived: sum of 2 quarters · filed 2017-03-06 | $27.43M derived: sum of 3 quarters · filed 2017-03-06 | $35.30M 10-K · filed 2017-03-06 |
| 2014-09-30 | $6.76M 10-Q · filed 2015-11-05 | $14.51M derived: sum of 2 quarters · filed 2015-11-05 | $22.38M 10-Q · filed 2015-11-05 | $28.17M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $7.75M 10-Q · filed 2015-08-05 | $15.61M 10-Q · filed 2015-08-05 | $21.41M derived: sum of 3 quarters · filed 2016-03-11 | $27.22M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $7.87M 10-Q · filed 2015-05-05 | $13.66M derived: sum of 2 quarters · filed 2016-03-11 | $19.47M derived: sum of 3 quarters · filed 2016-03-11 | $24.07M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $11.61M derived: sum of 2 quarters · filed 2016-03-11 | $16.21M derived: sum of 3 quarters · filed 2016-03-11 | $20.04M 10-K · filed 2016-03-11 |
| 2013-09-30 | $5.81M 10-Q · filed 2014-11-05 | $10.41M derived: sum of 2 quarters · filed 2014-11-05 | $14.25M 10-Q · filed 2014-11-05 | $18.53M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $4.60M 10-Q · filed 2014-08-05 | $8.43M 10-Q · filed 2014-08-05 | $12.71M derived: sum of 3 quarters · filed 2015-03-12 | $13.98M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $3.83M 10-Q · filed 2014-05-08 | $8.11M derived: sum of 2 quarters · filed 2015-03-12 | $9.38M derived: sum of 3 quarters · filed 2015-03-12 | $15.21M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $5.55M derived: sum of 2 quarters · filed 2015-03-12 | $11.37M derived: sum of 3 quarters · filed 2015-03-12 | $20.09M 10-K · filed 2015-03-12 |
| 2012-09-30 | $1.27M 10-Q · filed 2013-11-12 | $7.09M derived: sum of 2 quarters · filed 2013-11-12 | $15.81M 10-Q · filed 2013-11-12 | $27.33M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $5.83M 10-Q · filed 2013-08-09 | $14.54M 10-Q · filed 2013-08-09 | $26.06M derived: sum of 3 quarters · filed 2014-03-14 | $35.88M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | $8.71M 10-Q · filed 2013-05-10 | $20.23M derived: sum of 2 quarters · filed 2014-03-14 | $30.05M derived: sum of 3 quarters · filed 2014-03-14 | $40.20M derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $11.52M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $21.34M derived: sum of 2 quarters · filed 2014-03-14 | $31.49M derived: sum of 3 quarters · filed 2014-03-14 | $31.49M 10-K · filed 2014-03-14 |
| 2011-09-30 | $9.82M 10-Q · filed 2012-11-01 | $19.97M derived: sum of 2 quarters · filed 2012-11-01 | $19.97M 10-Q · filed 2012-11-01 | |
| 2011-06-30 | $10.15M 10-Q · filed 2012-08-07 | $10.15M 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |